• Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT, Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bodet-Milin C, Bailly C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Oncotarget 2018, 9:27502-27513

  • Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging, Le Bihan T, Navarro AS, Le Bris N, Le Saëc P, Gouard S, Haddad F, Gestin JF, Chérel M, Faivre-Chauvet A, Tripier R, Org Biomol Chem. 2018, 16:4261-4271

  • Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C, Oncotarget 2018, 9:9061-9072

  • Pretargeting in the context of theranostics and companion diagnostics in nuclear oncology. Barbet J. Clin Transl Imaging. (2018) 1-9.

    Translational molecular imaging in exocrine pancreatic cancer. Cornelissen B, Knight JC, Mukherjee S, Evangelista L, Xavier C, Caobelli F, Del Vecchio S, Rbah-Vidal L, Barbet J, de Jong M, van Leeuwen FWB. Eur J Nucl Med Mol Imaging. (2018)45, 2442-2455.

    Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study, Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C , Clin Cancer Res. 2018, 24:5219-5224 IF 10.199 JIF 94.820

  • Theranostic radioimmunotherapy (RIT) combined with immunotherapy : The best way to go ? Jean-François Chatal*, Med Res Innov, 2017 doi : 10.15761/MRI.1000119

    Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial : Innovative Radiopharmaceuticals in Oncology and Neurology. Front Med (Lausanne). 2017 Jan 11 ;3:74. doi : 10.3389/fmed.2016.00074. eCollection 2016.

    Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. C. Bailly et al. (accpeté pour publication dans Oncotarget)

    “Immuno-PET for Clinical Theranostic Approaches« . Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickaël Bourgeois, François Guérard, Ferid Haddad, Jacques Barbet, Michel Chérel, Françoise Kraeber-Bodéré, Thomas Carlier and Caroline Bodet-Milin. International Journal of Molecular Sciences 2017, 18 (1), 57 2017

    Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J. EJNMMI radiopharm. chem. (2017) 2 : 6. https://doi.org/10.1186/s41181-017-0026-8

    van Leeuwen FWB, Cornelissen B, Caobelli F, Evangelista L, Rbah-Vidal L, Del Vecchio S, Xavier C, Barbet J, de Jong M. EJNMMI radiopharm. chem. (2017) 2 : 15. https://doi.org/10.1186/s41181-017-0034-8

    Bourgeois M, Bailly C, Guerard F, Cherel M, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C. Radioimmunoconjugates for treating cancer : recent advances and current opportunities. Expert Opin Biol Ther 2017, 4 : 1-7 IF 3.684

    Frindel M, Le Saëc P, Beyler M, Navarro AS, Saï-Maurel C, Alliot C, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer. RSC Adv. 2017, 7 : 9272 IF 3.108

    Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C. Initial FDG-PET/CT predicts survival in adults ewing sarcoma family of tumors Oncotarget 2017, 8:77050-77060 IF 5.168

  • Radioimmunotherapy for Treatment of Acute Leukemia, Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P. (2016), Semin Nucl Med. 46 : 135-146.

    ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Françoise Kraeber-Bodere, Clément Bailly, Michel Chérel, Jean-François Chatal Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-016-3458-6

  • Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Bodet-Milin C, Ferrer L, Rauscher A, Masson D, Rbah-Vidal L, Faivre-Chauvet A, Cerato E, Rousseau C, Hureaux J, Couturier O, Salaün PY, Goldenberg DM, Sharkey RM, Kraeber-Bodéré F, Barbet J (2015) Front Med (Lausanne), 2 : 84.

    Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging. Colombié M, Gouard S, Frindel M, Vidal A, Chérel M, Kraeber-Bodéré F, Rousseau C, Bourgeois M (2015) Front Med (Lausanne). 2 : 58.

    Single-Dose Anti-CD138 Radioimmunotherapy : Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M (2015) Front Med (Lausanne), 2 : 76.

    Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy ? Guérard F, Barbet J, Chatal JF, Kraeber-Bodéré F, Chérel M, Haddad F. (2015) Q J Nucl Med Mol Imaging. 59 : 161-167. (IRON et ArronaxPlus)

    A pretargeting system for tumor PET imaging and radioimmunotherapy Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. (2015) Front Pharmacol. 6 : 54.

    Radioimmunotherapy : from current clinical success to future industrial breakthrough ? Kraeber-Bodéré F, Barbet J, Chatal JF (2015) J Nucl Med. 2015 Oct 29.

    • 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Salaün PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. (2014) Eur J Nucl Med Mol Imaging. 41, 1501-10.
    • A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation.Sas N, Rousseau J, Nguyen F, Bellec E, Larrsson E, Becavin S, Hindorf C, Abadie J, Chouin N, Barbet J. (2014) J Nucl Med. 55, 1355-1360.
    • Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia.Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S. (2014) PLoS One. 9:e87210.
  • Bodet-Milin, C., Ferrer, L., Pallardy, A., Eugène, T., Rauscher, A., Faivre-Chauvet, A., Barbet, J., Kraeber-Bodéré, F. (2013) Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma. Front Oncol. 3, 177.

    Carlier, T., Eugène, T., Bodet-Milin, C., Garin, E., Ansquer, C., Rousseau, C., Ferrer, L., Barbet, J., Schoenahl, F., Kraeber-Bodéré, F. (2013) Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Res. 3, 11.

    Chérel, M., Gouard, S., Gaschet, J., Saï-Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J.F., Kraeber-Bodéré, F., Barbet, J., Moreau, P., Davodeau, F. (2013) 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. J. Nucl. Med. 54, 1597-1604.

    Frampas, E., Rousseau, C., Bodet-Milin, C., Barbet, J., Chatal, J.F., Kraeber-Bodéré, F. (2013) Improvement of radioimmunotherapy using pretargeting. Front Oncol. 3, 159.

    Laffon, E., Bardiès, M., Barbet, J., Marthan, R. (2013) Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value. EJNMMI Res. 3, 26.

    Mauxion, T., Barbet, J., Suhard, J.M., Pouget, J.P., Poirot, M., Bardiès, M. (2013) Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med Phys. 40, 052501.

    Rousseau, C., Kraeber-Bodéré, F., Barbet, J., Chatal, J.F. (2013) Pretargeted radioimmunotherapy : clinically more efficient than conventional radioimmunotherapy ? Eur J Nucl Med Mol Imaging. 40, 1373-1376.

    Chatal JF, Barbet J, Kraber-Bodéré F, Goldenberg DM. Medullary Thyroid Carcinoma. In : Nuclear Medicine Therapy : Principles and clinical applications. C. Aktolun et S.J. Goldsmith (eds.), Springer Verlag+Business Media, New-York, 2013.

    Barbet, J., Chatal, J.F. Cyclotron-based Radiopharmaceuticals for Nuclear Medicine Therapy. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.

    Kraeber-Bodéré, F., Faivre-Chauvet, F., Bodet-Milin, C., Wegener, W.A., Chatal, J.F., Goldenberg, D.M. Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.

    • Barbet J, Bardiès M, Bourgeois M, Chatal JF, Chérel M, Davodeau F, Faivre-Chauvet A, Gestin JF, Kraeber-Bodéré F. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012, 907, 681-697.
    • Chatal JF, Kraeber-Bodéré F, Goldenberg DM. Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib : Need to stratify patients on basis of calcitonin doubling time. J Clin Oncol. 2012, 30, 2165.